Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD30 + status confers therapeutic sensitivity to Bendamustine, Brentuximab Vedotin in patients with Hodgkin Lymphoma.
The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with bendamustine for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).